| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Merck KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2,878.21 |
| 52 Week High | €2,878.21 |
| 52 Week Low | €2,878.21 |
| Beta | 0.69 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -19.74% |
| 5 Year Change | n/a |
| Change since IPO | -14.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| MRK1 N | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | -0.9% | -0.8% |
| 1Y | n/a | -16.2% | 4.5% |
Return vs Industry: Insufficient data to determine how MRK1 N performed against the MX Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how MRK1 N performed against the MX Market.
Price Volatility
| MRK1 N volatility | |
|---|---|
| MRK1 N Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in MX Market | 5.9% |
| 10% least volatile stocks in MX Market | 2.3% |
Stable Share Price: MRK1 N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MRK1 N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1668 | 62,345 | Belen Garijo Lopez | www.emdgroup.com |
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.
Merck KGaA Fundamentals Summary
| MRK1 N fundamental statistics | |
|---|---|
| Market cap | Mex$1.30t |
| Earnings (TTM) | Mex$49.02b |
| Revenue (TTM) | Mex$374.94b |
26.5x
P/E Ratio3.5x
P/S RatioIs MRK1 N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRK1 N income statement (TTM) | |
|---|---|
| Revenue | €20.82b |
| Cost of Revenue | €8.70b |
| Gross Profit | €12.12b |
| Other Expenses | €9.40b |
| Earnings | €2.72b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 01, 2024
| Earnings per share (EPS) | 6.26 |
| Gross Margin | 58.23% |
| Net Profit Margin | 13.07% |
| Debt/Equity Ratio | 35.5% |
How did MRK1 N perform over the long term?
See historical performance and comparison